About the Authors

Donna E. Leet

Roles Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing

donna.leet@ucsf.edu

Affiliation Department of Medicine, University of California, San Francisco, California, United States of America

Jing Jin

Roles Formal analysis, Writing – review & editing

Affiliation Vitalant Research Institute, San Francisco, California, United States of America

Charles S. Craik

Roles Funding acquisition, Supervision, Writing – review & editing

Affiliation Department of Pharmaceutical Chemistry, University of California, San Francisco, California, United States of America

Michael G. Kattah

Roles Software, Supervision, Writing – review & editing

Affiliation Department of Medicine, University of California, San Francisco, California, United States of America

Millie D. Long

Roles Project administration, Supervision, Writing – review & editing

Affiliation Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America

Uma Mahadevan

Roles Conceptualization, Data curation, Funding acquisition, Supervision, Writing – review & editing

Affiliation Department of Medicine, University of California, San Francisco, California, United States of America

Competing Interests

D.E.L. has received consulting fees from Neptune Medical. M.K. receives research support from Eli Lilly for work unrelated to this submission. M.K. is a member of the scientific advisory boards of Santa Ana Bio and Switchback Therapeutics and has received consulting fees from Cellarity, Spyre Therapeutics, Morphic Therapeutic, Sonoma Biotherapeutics, and Surrozen. M.D.L. receives research support from Lilly, Takeda, and Pfizer and is a consultant for AbbVie, BMS, Celltrion, Janssen, Intercept, Lilly, Pfizer, Prometheus, Takeda, and Target RWE. U.M. is a consultant for Abbvie, Abivax, Bristol Myers Squibb, Boeringher Ingelheim, Celltrion, Disc, Enveda, Genentech, Gilead, Janssen, Lilly, Pfizer, Protagonist, Roivant, Trex and Takeda, and advises for Rani Therapeutics (SAB) and Merck/Prometheus Biosciences (DSMB). Royalties: UptoDate. J.J.: none to report. C.S.C.: none to report. This does not alter our adherence to PLOS ONE policies on sharing data and materials.